Overview

A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)

Status:
RECRUITING

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Anaveon AG

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

pembrolizumab